JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
Recruiting
Phase 2
Interventional Study
Small-cell Lung Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 30 (estimated)
- Sponsor
- Hunan Province Tumor Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a prospective, single-arm phase II clinical study to evaluate the efficacy and safety of JS-201 combined with lenvatinib in the treatment of small-cell lung cancer that has failed previous chemotherapy combined with PD-L1. The primary observational endpoint is ORR, and the secondary observational endpoint is PFS, OS. The intervention mode is JS201 300mg i.v Q2w, lenvatinib 8mg po. Qd.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* 1\. The imaging diagnosis is the extensive stage of SCLC
* 2\. The patient failed first-line EC+PD-L1 treatment
* 3 PS 0-1
Exclusion Criteria:
* 1\. Diagnosed as non-small cell lung cancer
* 2\. Women during pregnancy
* 3\. Patients with symptomatic brain metastases
* 4\. PS…
Contacts